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Since its introduction over 10 years ago and de-
spite the ongoing importance of treatment and
prophylaxis of opportunistic infections, highly
active antiretroviral therapy (HAART) has be-
come the mainstay of management of patients
infected with HIV. HAART uses a combination of
antiviral drugs to interrupt the life cycle of the
virus and can usually suppress viremia to levels
below that detectable by conventional assays, i.e.
50 copies of viral RNA per milliliter (equivalent
to 25 viruses since they have dimeric [diploid]
genomes). The introduction of HAART in an in-
fected patient is associated with a dramatic drop
in viral load within 2 weeks. This is associated
with a slower developing, but nonetheless pro-
gressive, degree of immune reconstitution. Despite
its success, viral eradication from an infected per-
son has never been attained, and thus HAART
must be lifelong. Cessation of therapy results in
viral reappearance in the circulation within 2
weeks.1,2
Viral Reappearance
Where does the recrudescent virus come from?
There are two possible sources. One is that very
low level viral replication, below the threshold of
detection of current assays, persists and can then
escape after the cessation of HAART.3 Two observa-
tions support this theory: ultrasensitive techniques
can in fact detect very low level viremia in patients
treated by HAART and this low level can be further
reduced by intensification of antiviral therapy.4
Secondly, there is evidence that unintegrated viral
DNA, a marker of ongoing viral replication, is
present in patients treated with HAART.5 Indeed,
on sequential sampling, the detectable DNA se-
quences of unintegrated (episomal) viruses from
patients undergoing suppressive HAART evolve to
become drug resistant.6 Together, these observa-
tions suggest that HAART, while inhibiting most
viruses or rendering them non infectious, either
does not penetrate in sufficient concentrations to
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all sites of virus replication or that it is not 100%
inhibitory and that some viruses can still repli-
cate, albeit inefficiently, despite the presence of
“therapeutic” blood levels of the drugs.
An alternative source for viral rebound is that
it comes from the reactivation of latent viruses.
After entering the infected cell, the virus reverse
transcribes its RNA genome into double-stranded
DNA. The double-stranded viral DNA is incorpo-
rated into the host genome, a process termed in-
tegration. Subsequently, during virus production,
the virus utilizes host machinery for transcrip-
tion of the integrated proviral genome to pro-
duce viral RNA and hence proteins. The integrated
provirus genome is a stable molecular form of the
virus which will persist and be reproduced and
transmitted to each daughter cell at mitosis. This
viral DNA may not be transcriptionally active, re-
sulting in a pool of latently infected cells. There
is good evidence for this: in cells from infected
patients, viral DNA, presumably representing inte-
grated viruses, is detected approximately 10 times
more frequently than viral RNA, suggesting that
the majority of the integrated viral genomes are
not transcribing to produce viral RNA.7–9 Sec-
ondly, viruses recovered in viral rebound after ces-
sation of HAART10,11 and from patients with low
level viremia in the presence of HAART12 contain
drug-sensitive genotypes or archival genotypes that
show resistance to previously employed agents
and not those used in that patient’s most recent
HAART. This suggests that these viruses had not
been replicating recently but had been reactivated
from latency. Thirdly, mathematical modeling of
virus turnover during low level viremia under
HAART shows minimal viral replenishment,13
arguing that the stability of the numbers of latent
viruses could not be derived from persistence
and reseeding (although the detectable viremia
could).14
Mechanisms of Latency
The cellular biology of HIV latency and silencing
is starting to be elucidated. In vitro analysis has
shown that the major hurdles in the viral life
cycle are viral entry into the cell and, subsequently,
initiation of viral gene expression.15 In vitro in
single round replication assays, the level of unin-
tegrated HIV species peaks at 7 hours post infec-
tion but subsequently falls to a low level by 26
hours.16 Thus, unintegrated HIV species are too
unstable to be the dormant molecular form of
the virus, and the likely source of latent viruses is
silent integrated proviruses.
After integration, viral gene expression bifur-
cates to either high level gene expression or extinc-
tion17 (once established, viral gene expression is
extremely durable—lasting for at least 18 months
in one study).18 Such a reproducibly binary pattern
of expression is postulated to be a result of a pos-
itive feedback loop mediated by the viral protein
Tat, which stimulates further viral gene expression
by acting on a responsive element in the viral
promoter.17 Thus, latently infected cells are likely
to contain silent, rather than partially expressed,
proviruses.
What is the cause of such silencing (see Figure)?
In vitro studies showed that silencing is observed
frequently, even in actively dividing cells,18,19 sug-
gesting that it may be an intrinsic property of the
viral promoter system. The site of provirus integra-
tion in the DNA of the cell is potentially impor-
tant: gene expression from an integrated virus is
partially determined by its location in the ge-
nome.20 This site-dependent effect is mediated,
at least in part, by the permissiveness of the DNA
and DNA binding proteins—the chromatin—at
the site of integration. The critical effect of chro-
matin structure is supported by examination at a
local level using techniques such as chromatin
histone immunoprecipitation (CHIP) assays21–23
and can also be inferred from reactivation exper-
iments where pharmacologic agents that alter
the chromatin structure can alter the level of viral
gene expression.24,25 The importance of chro-
matin structure is also apparent from studies of
retrovirus-based viral vectors for gene therapy,
where the incorporation of a genetic element that
can affect the local chromatin can later influence
the level of vector gene expression.26,27 The local
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chromatin structure however is not the sole de-
termining factor. While the level of HIV gene ex-
pression increases with higher gene density at the
site of integration, very highly expressed regions
of the genome exist that are not favored for integra-
tion or expression, suggesting the presence of more
subtle rules governing the behavior of the pro-
virus.20 More importantly, variegation—a differ-
ence in phenotype within a clonal population—
has also been observed, arguing that further mod-
ulation can occur within a single cell.17,18 There-
fore, it is also possible that chromatin remodeling
is a final common pathway to gene silencing rather
than its primary cause. Other factors implicated
in proviral silencing include the availability/lack
of specific cellular transcription factors. Over 100
transcription factors have been shown to bind to
the HIV promoter,28 of which the effect of NFκB
is the best demonstrated. The intracellular level
of NFκB fluctuates in a cyclical manner29 and it
is plausible that this could affect the behavior of
the provirus. An innate genome defence against
invading molecular parasite has also been postu-
lated. There are reports of elevated level of DNA
methyltransferase—an enzyme that mediates
DNA methylation that leads to tight chromatin
repression—after HIV infection.30 More recently,
repression of viral gene expression by viral31 and
cellular32 microRNA has also been described.
Latency In Vivo
The biology of latency in vivo is less clear. Studies
of latency in vivo have been problematic: latently
infected cells by definition do not display any
protein markers for the cells to be selected 
for study without their biological characteristics
being perturbed.33 However, the molecular sta-
bility achieved by viral integration into the host
HIV latency and reactivation
J Formos Med Assoc | 2008 • Vol 107 • No 12 911
Figure. Processes of viral gene expression and mechanisms of viral silencing.
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genome and the cellular stability of resting CD4
T cells offers an elegant hypothesis: that latently
infected cells are generated as the virus infects ac-
tivated CD4 T cells that are returning to a quiescent
state.34 Indeed, it was possible to detect viral gene
products in quiescent CD4 T cells after cellular
activation.34–36 Based on this, many researchers
study the latent pool by identifying resting CD4
T cells that produce viral proteins after cytokine
stimulation.33 This approach depends on latent
viruses being efficiently reactivated by the chosen
stimulatory method and assumes that the clini-
cally important latent pool is in the resting CD4
compartment. The overall picture however sug-
gests something more complex. As discussed ear-
lier, a large proportion of proviruses are silent 
in vitro, even in dividing cells.19 Early studies per-
forming in situ PCR for viral DNA from untreated
patients also showed a large proportion of silent
proviruses,7,8 yet latently infected cells identified
by cytokine reactivation after tissue harvesting
were found infrequently. An association between
HIV and follicular dendritic cells in lymphoid
tissues in patients treated with HAART has also
been demonstrated.37,38 In addition, the central
nervous system has been proposed as a reservoir
for latent viruses.39 Thus, there may be more than
one anatomic or tissue compartment contributing
to viral latency.
Therapeutic Approaches to Latent Virus
Latently infected cells offer no specific target for
antiviral treatment and immunologic clearance
and are thus “sanctuary” sites for the virus. A strat-
egy to achieve virus clearance is to therapeutically
reactivate latent virus followed by administration
of antiviral drugs while also depending on immune
clearance of the newly immunologically “visible”
infected cells. A number of agents such as histone
deacetylate inhibitors trichostatin A,22,25 pros-
tratin,40–42 cytokines such as IL-743 and TNF-α44
have demonstrated efficacy in vitro. Attempts in vivo
however have been disappointing. Previous stud-
ies combining the cytokine IL-2 with HAART in
infected patients showed that viral rebound was
the rule after cessation of HAART.45 More recently,
a study using the stimulant of histone deacety-
lase, valproic acid,46 in vivo caused considerable
excitement. The study quantified the latent pool
using cytokine stimulation of resting CD4 T cells
and found statistically significant reductions in the
size of the latent pool in four patients in whom
valproic acid was administered. Unfortunately,
enfuvirtide was added during the study period to
these four patients, making the interpretation of
results difficult. Furthermore, a beneficial effect
of valproic acid was not seen in patients who
were treated with the agent for other indications
but did not undergo intensification of therapy
with enfuvirtide47 or in other studies addressing
the same issue.48
What are the reasons for the disappointing out-
comes of experimental therapeutic reactivation?
One possibility is that latently infected cells re-
side in an immunologic sanctuary site or sites in-
adequately penetrated by HAART. Thus, despite
efficient reactivation, the latently infected cells are
not eliminated. Another possibility might be that
the reactivation regime was ineffective. At present,
these remain conjectural, reflecting the paucity
of understanding of the nature of the latent reser-
voir at the tissue level and of what are probably
multiple mechanisms involved in the arrest of the
virus life cycle at the cellular level.
Future Prospects for Eradicating 
Latent Virus
How should the hurdle of viral latency be tack-
led? Clearly, the nature of the latent reservoir in
vivo needs to be better defined. The assumption
that latency is an intrinsic property of the virus,
and once reactivated the latently infected cell
would be susceptible to immunologic clearance
or HAART, should be verified in vivo. Further
therapeutic reactivation studies could be pursued
using a combination of stimuli targeting many or
all of the viral silencing mechanisms so far iden-
tified to ensure efficient reactivation. The use of
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combination stimuli worked well in vitro in other
retroviruses in overcoming chromatin-mediated
latency49 and also in HIV.25 However, this may
involve a large number of pharmaceutical agents,
which may be unacceptably toxic or simply im-
practical. Perhaps a more modest but achievable
approach would be to identify the most impor-
tant mechanism(s) causing viral latency and to
target these selected few for reactivation. This could
reduce but would not eliminate the risk of viral
rebound. To do this, we require much more de-
tailed knowledge on the relative contribution of
each of the silencing mechanisms contributing to
virus latency and the nature of the latent reservoir.
Research on drugs targeting viral replication in
HIV has been one of the greatest therapeutic suc-
cesses in any branch of medicine in the last few
decades. The next challenge of eliminating the
latent virus reservoir is probably an even bigger
one but the rewards would be immense—true
elimination of HIV from an infected person.
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